n | Baseline | n | 8-year follow-up | N | 18-year follow-up | P value* | ||
Group 1 (MiDA-ID) | ||||||||
cJADAS10 | 70 | 1.7 (0–3.9) | 101 | 0 (0–0.1) | 147 | 0 (0–0.5) | <0.0001 | 0.40 |
Active joint count | 168 | 0 (0–1.0) | 168 | 0 (0–0) | 167 | 0 (0–0) | <0.0001 | 0.03 |
PaGA | 84 | 0.5 (0–1.5) | 123 | 0 (0–0) | 151 | 0 (0–0.5) | <0.0001 | 0.01 |
PhGA | 73 | 0.5 (0–1.0) | 103 | 0 (0–0) | 163 | 0 (0–0) | <0.0001 | 0.45 |
Group 2 (MiDA-MDA) | ||||||||
cJADAS10 | 55 | 2.2 (1.5–4.5) | 78 | 1.5 (0–3.7) | 94 | 4.0 (1.5–8.5) | 0.20 | 0.008 |
Active joint count | 104 | 0 (0–1.0) | 101 | 0 (0–1.0) | 104 | 0 (0–1.0) | 0.36 | 0.50 |
PaGA | 65 | 0.5 (0–1.5) | 83 | 0.2 (0–1.2) | 95 | 2.0 (0.5–4.5) | 0.28 | <0.0001 |
PhGA | 57 | 0.9 (0.3–1.2) | 81 | 0.5 (0–1.5) | 101 | 1.0 (0–2.0) | 0.29 | <0.0001 |
Group 3 (HDA-MiDA) | ||||||||
cJADAS10 | 71 | 8.4 (5.0–12.7) | 85 | 1.5 (0.2–4.0) | 113 | 1.0 (0–3.0) | <0.0001 | 0.33 |
Active joint count | 119 | 3.0 (2.0–5.0) | 115 | 0 (0–1) | 119 | 0 (0–0) | <0.0001 | 0.0004 |
PaGA | 76 | 2.2 (1.0–4.3) | 89 | 0.4 (0–1.9) | 115 | 0.5 (0–2.0) | <0.0001 | <0.0001 |
PhGA | 72 | 2.4 (1.0–4.2) | 86 | 0.3 (0–1.3) | 116 | 0 (0–0.5) | <0.0001 | 0.58 |
Group 4 (HDA-HDA) | ||||||||
cJADAS10 | 26 | 13.8 (6.6–19.0) | 27 | 7.8 (2.6–15.5) | 35 | 10.0 (6.5–14.0) | 0.08 | 0.46 |
Active joint count | 36 | 4.0 (2.5–10.0) | 36 | 2.5 (0–6.0) | 36 | 2.0 (0–3.5) | 0.01 | 0.38 |
PaGA | 26 | 2.8 (1.0–6.2) | 28 | 1.9 (0.5–5.1) | 35 | 4.0 (2.0–7.5) | 0.99 | <0.0001 |
PhGA | 27 | 4.4 (2.0–5.1) | 29 | 2.3 (0.8–5.0) | 36 | 3.0 (1.0–4.5) | 0.39 | <0.0001 |
Disease activity trajectory groups from baseline to 18-year follow-up.
Values are median IQR and total numbers.
*P value in the first column is for the difference between baseline and 8-year follow-up. P value in the second column is for the difference between 8-year and 18-year follow-up.
cJADAS10, clinical Juvenile Arthritis Disease Activity score (0–30); HDA, high disease activity; ID, inactive disease; MDA, moderate disease activity; MiDA, minimal disease activity; PaGA, patient global assessment of disease impact on well-being (0–10); PhGA, physician’s global assessment of disease activity (0–10).